Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer supplies pricing data to GAO

Executive Summary

Pfizer is turning over drug pricing data subpoenaed by the General Accounting Office, Pfizer CEO Henry McKinnell, PhD, reported Jan. 15. GAO's Jan. 3 subpoena gave the company until Jan. 14 to supply the documents (1"The Pink Sheet" Jan. 14, p. 26). "What was requested was pricing of individual products to individual customers," McKinnell said. "We were prepared to provide that information. However, we wanted to protect confidentiality. We agreed to those protections last week and the data has been provided"...

You may also be interested in...



Pfizer Pricing Data Subpoenaed By GAO As Part Of Medicaid Investigation

Pfizer has until Jan. 14 to respond to the General Accounting Office's request for documents related to price reporting practices under the Medicaid drug rebate program

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel